Nektar Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting

Thursday, March 2, 2017 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

Five Data Presentations Will Showcase Nektar's Immuno-oncology Candidates, NKTR-214 and NKTR-255

SAN FRANCISCO, March 1, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced five data presentations

will be delivered at the upcoming American Association for Cancer Research (AACR) Annual Meeting, which will be held April 1-5, 2017 at the Walter E. Washington Convention Center in Washington, D.C. Researchers will present new preclinical data on NKTR-214, the Company's immuno-stimulatory CD122-biased agonist, as well as on NKTR-255, the Company's IL-15 therapeutic candidate.

Details of the poster presentations are as follows:Abstract 1598/Poster 6: "Single agent NKTR-214, a biased IL2 pathway agonist, increases immune cell infiltrates in brain tumors and prolongs survival in rodent (rattus) glioblastoma (GBM)"Session: Cytokines: The First Modern ImmunotherapiesDate and Time: Monday, April 3, 2017, 8:00 AM - 12:00 PM Eastern TimeLocation: Convention Center, Halls A-C, Poster Section 26

Abstract 1603/Poster 11: "NKTR-255 engages the IL-15 pathway driving CD8 T cell survival and CD8 memory T cell proliferation"Session: Cytokines: The First Modern ImmunotherapiesDate and Time: Monday, April 3, 2017, 8:00 AM12:00 PM Eastern TimeLocation: Convention Center, Halls A-C, Poster Section 26

Abstract 1604/Poster 12: "NKTR-214 Synergizes with Radiotherapy to Drive Tumor Regression"Session: Cytokines: The First Modern ImmunotherapiesDate and Time: Monday, April 3, 2017, 8:00 AM12:00 PM Eastern TimeLocation: Convention Center, Halls A-C, Poster Section 26

Abstract 1617/Poster 25: "Mechanistic modeling of a new kinetically-controlled CD122 agonist for cancer immunotherapy: NKTR-214 pharmacokinetics, pharmacodynamics, and receptor pharmacology"Session: Cytokines: The First Modern ImmunotherapiesDate and Time: Monday, April 3, 2017, 8:00 AM12:00 PM Eastern TimeLocation: Convention Center, Halls A-C, Poster Section 26

Abstract 2671/Poster 30: "Antitumor activity of NKTR-214 in combination with Adopted Cell Transfer (ACT) in an aggressive murine melanoma"Session: Immune Response to Hematopoietic Tumors: New Development in Tumor ImmunologyDate and Time: Monday, April 3, 2017 1:00 PM5:00 PM Eastern TimeLocation: Convention Center, Halls A-C, Poster Section 26

About Nektar Therapeutics

Nektar Therapeutics is a research-based development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Contact:

For Investors:Jennifer Ruddock of Nektar Therapeutics415-482-5585

Jodi Sievers of Nektar Therapeutics415-482-5593

For Media:Dan Budwick of Pure Communications973-271-6085 [email protected]

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nektar-therapeutics-announces-upcoming-presentations-at-the-american-association-for-cancer-research-annual-meeting-300416349.html

SOURCE Nektar Therapeutics



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store